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Chlorine is a cost-effective drinking water dis-
infectant that has been used since the early 
twentieth century to control a panoply of 
water borne infectious diseases. By-products of 
the inter action of chlorine with organic pre-
cursors in water were first noted in 1974, with 
the discovery of trihalomethanes (THMs) 
in disinfected water (Bellar and Lichtenberg 
1974; Rook 1974). Since then, hundreds of 
halogenated chemical species in the disinfec-
tion by-product (DBP) mixture have been 
detected, including both brominated and 
chlorinated compounds (Richardson 2003). 
THMs and haloacetic acids (HAAs) are the 
chemical groups at highest concentration in 
most by-product mixtures. Toxicological and 
epidemiologic studies of DBPs provide evi-
dence of elevated risk of cancer and adverse 
birth outcomes (Cantor et al. 2006; Grellier 
et al. 2010; Nieuwenhuijsen et al. 2009). In 
particular, human bladder cancer has been 
consistently linked with long-term exposure 
(Cantor et al. 1998; King and Marrett 1996; 
McGeehin et al. 1993; Villanueva et al. 2004). 
These observations are supported by evidence 
of mutagenicity of the mixture and carcino-
genicity of some constituents (Komulainen 
2004; Richardson et al. 2007). To date, 
the role of genetic variability in modulating 
adverse health effects of DBPs has received 
limited attention (Infante-Rivard et al. 2002), 
and bladder cancer has not been studied in 
this regard.
At least three enzymes in the metabolic 
pathways of DBP components are candidates 
for examination. Glutathione S-transferase 
(GST) theta-1 (GSTT1) activates bromi-
nated THMs to mutagens in a transgenic 
strain of Salmonella (DeMarini et al. 1997; 
Pegram et al. 1997). GST zeta-1 (GSTZ1) 
catalyzes the oxygenation of dichloro- and 
other α-haloacids, some of which are animal 
carcino gens (DeAngelo et al. 1999; Melnick 
et al. 2007; Tong et al. 1998). Cytochrome 
P450 2E1 (CYP2E1) metabolizes a wide vari-
ety of aliphatic hydro carbons, solvents, and 
industrial monomers (Guengerich et al. 1991) 
and is responsible for the primary oxidation of 
THMs. Genes that code for these enzymes are 
polymorphic in human populations, with the 
GSTT1 deletion resulting in lack of enzyme 
activity, and with several non synonymous 
single-nucleotide polymorphisms (SNPs) in 
GSTZ1 and CYP2E1 resulting in modified 
enzymatic activity (Blackburn et al. 2001; 
Bolt et al. 2003). We hypothesized that one 
or more of these functional polymorphisms 
could influence bladder cancer risk posed by 
DBPs, and we investigated this in a large case–
control study in Spain, where in a previous 
study (Villanueva et al. 2007) we observed 
elevated risk of bladder cancer after long-term 
exposure to DBPs. 
Materials and Methods
We conducted a hospital-based case– control 
study in 18 hospitals located in five areas 
of Spain [Asturias, Barcelona metropolitan 
area, Valles/Bages (including the municipali-
ties of Manresa and Sabadell), Alicante, and 
Tenerife] (Appendix 1). Eligible cases were 
21–80 years of age, newly diagnosed with 
histologically confirmed urothelial carcinoma 
of the bladder between 1998 and 2001, and 
living in the catchment geographic area of 
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Background: Bladder cancer has been linked with long-term exposure to disinfection by-products 
(DBPs) in drinking water.
oBjectives: In this study we investigated the combined influence of DBP exposure and poly-
morphisms in glutathione S-transferase (GSTT1, GSTZ1) and cytochrome P450 (CYP2E1) genes 
in the metabolic pathways of selected by-products on bladder cancer in a hospital-based case–
control study in Spain.
Methods: Average exposures to trihalomethanes (THMs; a surrogate for DBPs) from 15 years of 
age were estimated for each subject based on residential history and information on municipal water 
sources among 680 cases and 714 controls. We estimated effects of THMs and GSTT1, GSTZ1, 
and CYP2E1 polymorphisms on bladder cancer using adjusted logistic regression models with and 
without interaction terms.
results: THM exposure was positively associated with bladder cancer: adjusted odds ratios (ORs) 
and 95% confidence intervals (CIs) were 1.2 (0.8–1.8), 1.8 (1.1–2.9), and 1.8 (0.9–3.5) for THM 
quartiles 2, 3, and 4, respectively, relative to quartile 1. Associations between THMs and bladder 
cancer were stronger among subjects who were GSTT1 +/+ or +/– versus GSTT1 null (pinteraction 
= 0.021), GSTZ1 rs1046428 CT/TT versus CC (pinteraction = 0.018), or CYP2E1 rs2031920 CC 
versus CT/TT (pinteraction = 0.035). Among the 195 cases and 192 controls with high-risk forms of 
GSTT1 and GSTZ1, the ORs for quartiles 2, 3, and 4 of THMs were 1.5 (0.7–3.5), 3.4 (1.4–8.2), 
and 5.9 (1.8–19.0), respectively.
conclusions: Polymorphisms in key metabolizing enzymes modified DBP-associated bladder can-
cer risk. The consistency of these findings with experimental observations of GSTT1, GSTZ1, and 
CYP2E1 activity strengthens the hypothesis that DBPs cause bladder cancer and suggests possible 
mechanisms as well as the classes of compounds likely to be implicated.
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participating hospitals. Cases were identified 
from the registers of urological services aug-
mented by regular and frequent evaluations of 
hospital discharge records, pathology records, 
and local cancer registries. A panel of expert 
pathologists confirmed diagnoses and ensured 
uniformity of classification criteria, based 
on the 1998 World Health Organization/
International Society of Urological Pathology 
system (Epstein et al. 1998).
Controls were selected from patients 
admitted to participating hospitals with con-
ditions thought to be unrelated to the major 
risk factors of bladder cancer, such as tobacco 
use. Diagnostic categories for controls were as 
follows: 37% hernias, 11% other abdominal 
surgery, 23% fractures, 7% other orthopedic 
problems, 12% hydrocoele, 4% circulatory 
disorders, 2% dermatological disorders, 1% 
ophthal mological disorders, and 3% other 
diseases. Controls were individually matched 
to cases by age at interview within 5-year 
strata, sex, ethnic origin, and hospital catch-
ment area, a well-defined area corresponding 
to the specific health services region covered 
by each hospital. Written informed consent 
was obtained from each subject before the 
study. The study was approved by the review 
board of each participating institution and 
in accord with an assurance filed with and 
approved by the U.S. Department of Health 
and Human Services.
Individual data. After obtaining informed 
consent, trained interviewers administered a 
computer-assisted personal interview (CAPI) 
to participants during their hospital stay. 
Interview items included socio demographic 
characteristics; smoking habits; occupational, 
residential, and medical histories; and familial 
history of cancer. We identified 1,457 eligible 
cases and 1,465 eligible controls. Of these, 
84% of cases (n = 1,219) and 87% of con-
trols (n = 1,271) participated. Subjects who 
refused to answer the CAPI were administered 
a reduced interview of critical items (21% of 
cases and 19% of controls). Questionnaire 
information on water-related exposures used in 
this analysis included residential history from 
birth [all residences of at least 1 year, drinking 
water source at each residence (municipal/bot-
tled/private well/other)] and swimming pool 
use as an adult. These data were collected from 
all participants, including those who responded 
to the critical items questionnaire.
Exposure data. Using a structured ques-
tionnaire, we collected historic water quality 
data from approximately 200 local authori-
ties and 150 water companies in the study 
areas. For 123 study municipalities, covering 
78.5% of the total study exposure-years, we 
obtained annual average THM levels. In addi-
tion, one of us (C.M.V.) measured levels of 
the four THMs [chloroform, bromo dichloro-
methane (BDCM), dibromo chloro methane, 
and bromo form] in 113 tap water samples 
from the studied geographic areas between 
September and December 1999.
Average THM levels in recent years were 
extrapolated back to approximately 1920. 
Historical THM levels were estimated by 
municipality under the assumption that past 
THM levels were similar to current concentra-
tions when the water source had not changed. 
When the water source had changed, we cal-
culated the average THM level using the pro-
portion of surface water during the rele vant 
time period. We assumed that the THM level 
before the start of chlorination was zero. The 
exposure assessment was described previously 
(Villanueva et al. 2006, 2007).
Lifetime individual exposure indices. We 
merged individual and municipal databases 
with individual residential information by year 
and municipality, and obtained individual year-
by-year average THM levels, water source, and 
chlorination status for each study subject. We 
used as an exposure metric the average THM 
level of the water source serving participant 
residences in the period between age 15 years 
and the interview, as described previously in 
the analysis of the main effects of DBP expo-
sure (Villanueva et al. 2007). As in that study, 
we restricted our analysis to subjects with a 
household THM estimate for at least 70% of 
the years in this exposure window.
Genotyping. DNA for genotype assays 
was extracted from leukocytes or mouthwash 
samples as described previously (Garcia-
Closas et al. 2005). Genotype assays for 
polymorphisms in GSTT1, GSTM1, and 
N-acetyltransferase 2 (NAT2) were con-
ducted at the Core Genotyping Facility of the 
Division of Cancer Epidemiology and Genetics 
(National Cancer Institute). The SNPs of 
NAT2 and assignments of rapid/intermediate/
slow acetylator types, as well as the GSTM1 
genotypes, have been described in detail else-
where (Garcia-Closas et al. 2005). GSTT1 
genotypes were defined as null (–/–) if a dele-
tion was found in both copies of the gene and 
present if one (+/–) or none (+/+) of the copies 
had a deletion. We used the TaqMan assay 
(Applied Biosystems, Foster City, CA, USA) 
for SNPs in NAT2, two of three SNPs in 
GSTZ1 [E32K (rs7975) and G42R (rs7972)], 
and deletions in GSTT1 and GSTM1. The 
methods for each specific assay are available 
from the National Cancer Institute (2010). 
A third SNP in GSTZ1 (T82M rs1046428) 
and three SNPs in CYP2E1 (IVS7–118C>G 
rs2070676, –1054C>T rs2031920, and 
–1514G>T rs8192766) were determined in a 
GoldenGate assay (Illumina, San Diego, CA, 
USA) (Garcia-Closas et al. 2007). All geno-
types studied were in Hardy-Weinberg equi-
librium in the control population. Duplicate 
quality control samples (n = 93 pairs) showed 
≥ 99% agreement for all assays.
Statistical analysis. We considered results 
to be statistically significant if the alpha level 
was ≤ 0.05. Subjects were grouped by quartile 
of the time-weighted average THM level since 
age 15 years. We used unconditional logistic 
regression to calculate odds ratios (ORs) and 
95% confidence intervals (CIs). ORs were 
adjusted for age (continuous), sex, smoking sta-
tus (never/former/current), size of the munici-
pality of longest residence until 18 years of age 
(reported by the participant as metropolis/city, 
small city, village, or farm), education (three 
strata: less than primary school, less than high 
school, and high school or more), geographic 
area (six strata: Barcelona, Sabadell, Manresa, 
Alicante, Tenerife, and Asturias), and overall 
quality of interview (reported by interviewer 
as unsatisfactory, questionable, reliable, or 
high quality). Analyses using more detailed 
smoking information (total duration, aver-
age daily number of cigarettes, tobacco type, 
pack-years) gave similar results and are not 
reported. Subjects were defined as “former” 
smokers if they had quit at least 1 year before 
the interview. Missing data for covariates were 
coded to a separate cate gory for each variable 
included in the models. This applied to a small 
proportion of respondents for each covariate. 
For example, < 1% of respondents were miss-
ing data on smoking status (Samanic et al. 
2006). Linear p-trends were calculated using a 
likelihood ratio test comparing the model with 
and without the THM exposure variable mod-
eled as a continuous variable with each quartile 
coded according to its median value.
Interactions between genotypes and expo-
sure to DBPs, as estimated by average THM 
levels serving the household between 15 years 
of age and diagnosis (cases) or interview (con-
trols), were also tested using the likelihood-ra-
tio test to allow estimation of parameters under 
the assumption of genotype–DBP (THMs) 
independence in the source population. 
Tests for multiplicative inter action were used 
to assess whether the genotype ORs within 
categories of DBP exposure or, equivalently, 
DBP ORs within geno type categories differed 
significantly from each other. Haplotype fre-
quencies for GSTZ1 and CYP2E1 were esti-
mated using HaploStats (version 1.2.1; http:// 
mayoresearch. mayo.edu/mayo/research/ 
biostat/ schaid.cfm) using the program language 
R (http://www.r-project.org/).
Results
Of the 1,219 cases and 1,271 controls inter-
viewed, 1,188 (97%) cases and 1,173 (92%) 
controls provided a blood or buccal cell sample 
for DNA extraction. After excluding cases and 
controls with low amounts of DNA, non white 
individuals (to limit hetero geneity), and DNA 
quality control difficulties, the study popu-
lation with adequate genetic material avail-
able for analysis numbered 1,150 cases and 
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1,149 controls (Garcia-Closas et al. 2005). 
After further excluding individuals with inad-
equate exposure data as described above, the 
maximum numbers with genotyping data 
were 680 cases (595 males, 85 females) and 
714 controls (622 males, 92 females). In each 
gene-specific analysis, we applied additional 
exclusions because of incomplete genetic 
 information. 
The ORs (95% CIs) for former [2.7 
(1.9–3.7)] and current [5.9 (4.2–8.5)] smok-
ers of cigarettes in the analysis data set, rela-
tive to never-smokers, paralleled those found 
in the full study population (Samanic et al. 
2006). The ORs (95% CIs) by increasing 
quartile of THMs were 1.0 (referent), 1.2 
(0.8–1.9), 1.8 (1.1–2.9), and 1.8 (0.9–3.5) 
(ptrend = 0.029) (Table 1), similar to the find-
ings of Villanueva et al. (2007). These ORs are 
adjusted for the covariates listed above, as are 
all subsequent ORs reported here. Findings 
from Garcia-Closas et al. (2005), from this 
study population, showed significant associa-
tions between bladder cancer and NAT2 slow 
acetylator compared with rapid/intermediate 
geno types [OR (95% CI) of 1.4 (1.2–1.7)] 
and GSTM1 null (–/–) versus GSTM1 pres-
ent genotypes [1.7 (1.4–2.0)]. Estimates in 
the present analyses were similar, with NAT2 
(slow compared with rapid plus inter mediate 
acetylator type) having an OR (95% CI) of 
1.33 (1.06–1.68), and with GSTM1 null 
compared with the GSTM1 present geno type 
having an OR (95% CI) of 1.77 (1.41–2.22). 
We found slightly elevated, non significant 
risks for GSTT1 presence compared with null 
[1.21 (0.92–1.59)]. The association for the 
inverse relationship (null vs. presence) was 0.81 
(0.61–1.09). In the full study, compared with 
the homozygous presence of GSTT1, the ORs 
(95% CIs) were 1.2 (1.0–1.5) for hetero zygotes 
(+/–) and 1.0 (0.8–1.3) for homo zygous null 
(–/–) (Garcia-Closas et al. 2005).
We found non significant elevations or 
decreases in risk for the three functional SNPs 
of GSTZ1 and the three variants of CYP2E1 
that we tested. Associations for the three SNPs 
in GSTZ1 and the three in CYP2E1 have not 
been reported previously. The GSTZ1 SNPs 
were in linkage dis equilibrium (pairwise D´ 
values ranged from 0.98 to 1.0); however, 
they were not highly correlated with each 
other (r2 ranged from 0.02 to 0.18). Of the 
three CYP2E1 SNPs tested, rs8192766 was 
not in linkage disequilibrium with rs2070676 
(D´ = 0.34). The other two pairs were in 
linkage dis equilibrium (D´ ≥ 0.98). None of 
the three CYP2E1 SNPs was highly correlated 
with any other (r2 ranged from 0.006 to 0.34). 
Haplotype analysis for GSTZ1 and the three 
SNPs genotyped revealed no common haplo-
type significantly associated with risk (global 
p = 0.80; data not shown). We made similar 
observations for CYP2E1 (global p = 0.76).
We observed significant interactions with 
THMs for GSTT1 (present vs. null) (pinteraction 
= 0.021), exon 7 +29T>C rs1046428 in 
GSTZ1 (pinteraction = 0.018), and –1054C>T 
rs2031920 in CYP2E1 (pinteraction = 0.035; 
Table 2) but not for the other two SNPs in 
GSTZ1 that we tested (rs7975, rs7972) or 
for the two other SNPs tested in CYP2E1 
(rs2070676, rs8192766; data not shown). 
We found no significant trends in associations 
with increasing THM quartiles among subjects 
with the GSTT1 null, GSTZ1 CC, or CYP2E1 
CT/TT genotypes; however, we did find sig-
nificant positive trends with increasing THM 
exposure among subjects with the GSTT1 
present genotype GSTZ1 CT/TT, or CYP2E1 
CC (Table 2). Haplotype analysis for GSTZ1 
and CYP2E1 did not provide additional infor-
mation beyond the single SNP analysis (data 
not shown). We found no evidence of inter-
action between either NAT2 slow acetylator 
or GSTM1-null genotype and long-term aver-
age THM level (pinteraction = 0.95 and 0.79, 
respectively; data not shown).
Because of small numbers of subjects 
(37 cases, 42 controls) with the CT variant 
of CYP2E1 rs2031920 (no subjects carried 
the TT variant), it was not possible to analyze 
a three-way interaction that included these 
subjects. We found a significant inter action 
between average THM level and combined 
GSTT1 and GSTZ1 rs1046428 genotypes 
(pinteraction = 0.0052) in analyses that included 
Table 1. ORs (95% CIs) for bladder cancer for 
quartile levels of average long-term level of 
household THMs and for selected SNPs. 
Measure
n (cases/
controls)a OR (95% CI)b p-Value
Average THM level at home (μg/L, age 15 to index age)
≤ 8.0 156/175 1.0
> 8.0–26.0 153/174 1.2 (0.8–1.9)
> 26.0–49.0 197/169 1.8 (1.1–2.9)
> 49.0 174/196 1.8 (0.9–3.5)
ptrend 0.029
Polymorphism
NAT2 
Fast 243/299 1.00
Slow 428/403 1.33 (1.06–1.68) 0.01
GSTM1 
Present 257/366 1.00
Null 420/346 1.77 (1.41–2.22)  < 0.001
GSTT1 
Null 136/160 1.00
Present 542/550 1.21 (0.92–1.59) 0.13
GSTZ1
rs1046428, T82M
CC 405/402 1.00
CT 213/213 1.06 (0.82–1.35) 0.67
TT 31/29 1.07 (0.61–1.86) 0.82
rs7975, E32K
GG 314/330 1.00
AG 275/276 1.06 (0.83–1.34) 0.66
AA 68/63 1.22 (0.82–1.81) 0.33
rs7972, G42R
GG 553/572 1.00
AG 100/91 1.16 (0.84–1.61) 0.36
AA 4/6 0.69 (0.18–2.56) 0.57
CYP2E1
rs2070676
CC 479/474 1.00
CG 161/166 0.93 (0.71–1.21) 0.59
GG 9/5 2.03 (0.62–6.62) 0.24
rs2031920
CC 590/569 1.00
CT 37/42 0.76 (0.47–1.23) 0.27
TT 0/0 —
rs8192766
GG 528/533 1.0
GT 118/106 1.05 (0.77–1.42) 0.77
TT 3/7 0.32 (0.08–1.30) 0.11
aNumbers of cases or controls per measure may not 
equal the total number of cases (680) and controls (714) 
because of missing genotype data. bOR (95% CI) from 
logistic regression adjusted for age (continuous), sex, 
smoking status (never/former/current), size of the munic-
ipality of longest residence until 18 years of age, edu-
cation (three strata), geographic area (six strata), and 
overall quality of interview.
Table 2. Interaction between average THM exposure and polymorphic forms of three genes: GSTT1, 
GSTZ1, and CYP2E1.a 
Gene, average THM (μg/L) n (cases/controls) OR (95% CI) n (cases/controls) OR (95% CI) pinteractionb
GSTT1 Null Present
≤ 8.0 34/34 1.0 (reference) 121/141 1.0 (reference)
> 8.0–26.0 36/37 1.2 (0.5–2.5) 116/136 1.2 (0.7–1.9)
> 26.0–49.0 37/41 1.2 (0.5–2.5) 160/126 2.0 (1.2–3.4)
> 49.0 29/48 1.0 (0.4–2.5) 145/147 2.2 (1.1–4.3) 0.021
ptrend 0.28 0.0072
GSTZ1 rs1046428 CC CT/TT
≤ 8.0 95/86 1.0 (reference) 52/62 1.0 (reference)
> 8.0–26.0 100/102 1.1 (0.7–1.9) 47/54 1.4 (0.7–2.7)
> 26.0–49.0 116/97 1.5 (0.9–2.7) 73/62 2.2 (1.1–4.2)
> 49.0 94/117 1.3 (0.6–2.8) 72/64 2.9 (1.3–6.7) 0.018
ptrend 0.28 0.0043
CYP2E1 rs2031920 CT/TT CC
≤ 8.0 15/9 1.0 (reference) 125/132 1.0 (reference)
> 8.0–26.0 10/14 0.98 (0.4–2.5) 133/141 1.3 (0.8–2.0)
> 26.0–49.0 9/11 1.1 (0.4–3.1) 176/134 2.1 (1.2–3.5)
> 49.0 3/8 0.6 (0.1–2.7) 156/162 2.0 (1.0–4.1) 0.035
ptrend 0.33 0.014
aORs (95% CIs) from logistic regression adjusted for age (continuous), sex, smoking status (never/former/current), size 
of the municipality of longest residence until 18 years of age, education (three strata), geographic area (six strata), and 
overall quality of interview. bp-Value for multiplicative interaction between THM level and the respective polymorphism.
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subjects with both the variant and common 
forms of CYP2E1 rs2031920 (Table 3). 
Among subjects with both GSTT1 present 
and GSTZ1 CT/TT genotypes, OR increased 
monotonically to 5.9 (95% CI, 1.8–19.0) in 
the highest quartile of THMs (ptrend = 0.0012). 
In contrast, among subjects with both GSTT1 
null and GSTZ1 CC genotypes, we found 
no increase in relative risk with increas-
ing THM level (pinteraction = 0.0052). These 
analyses excluded subjects with both low-risk 
variants of GSTZ1 and high-risk variants of 
GSTT1, or vice versa. When we restricted this 
analysis to subjects with the common form 
(CC) of CYP2E1 rs2031920, among those 
with both GSTT1 present and GSTZ1 CT/
TT genotypes, the OR increased monotoni-
cally to 9.3 (2.5–34.0) in the highest quartile 
of THM exposure (> 49.0 µg/L), relative to 
participants with these genotypes in the low-
est quartile [≤ 8.0 µg/L; ptrend = 0.0006 with 
pinteraction = 0.010; see Supplemental Material, 
Table 1 (doi:10. 1289/ehp.1002206)].
We calculated the main effects for the 
respective SNPs within increasing quartile 
strata of long-term average THMs (Table 4) 
where we found increasing relative risks for 
bladder cancer for GSTT1 present, GSTZ1 
rs1046428 CT/TT, and CYP2E1 rs2031920 
CC. Among subjects with exposure to THMs 
in the highest quartile, the ORs were elevated 
and the 95% CIs excluded 1.0 for GSTT1 
present (vs. GSTT1 null), GSTZ1 (CT/TT vs. 
CC), and CYP2E1 (CC vs. CT/TT), whereas 
ORs for these polymorphisms were close to 1.0 
among subjects in the lowest THM exposure 
quartile. The associations with bladder cancer 
risk for NAT2 slow versus rapid/intermediate 
acetylator and GSTM1 null versus present 
within each THM stratum were variable and 
consistent with the overall elevated main effects 
for these genes.
In earlier analyses of these data, we found a 
significant association with ever swimming in 
pools [OR = 1.62 (95% CI, 1.20–2.19)] but 
no association with increasing hours of lifetime 
pool use (Villanueva et al. 2007). There was no 
significant difference in risk for ever swimming 
in pools with any of the genetic polymorphisms 
under evaluation here. The weak statistical 
interactions observed with GSTT1 present (vs. 
GSTT1 null) and with GSTZ1 CT/TT (vs. 
CC) were in a direction contrary to expec-
tation, given what we observed for interac-
tions with THMs [see Supplemental Material, 
Table 2A,B (doi:10. 1289/ehp.1002206)].
Discussion
DBPs were previously found to be a blad-
der cancer risk factor in this case–control 
study in Spain, as well as in other settings 
(Villanueva et al. 2004, 2007). In the present 
study we found significant differences in the 
dose– response relation of bladder cancer risk 
with increasing average long-term exposure to 
DBPs (as represented by THMs) among sub-
jects with differing genotypes in each of three 
candidate genes. GSTT1 and GSTZ1 code for 
enzymes in the respective biotransformation 
pathways of two groups of DBPs, the bromi-
nated THMs and the α-haloacids. CYP2E1 
oxidizes THMs and likely many other com-
pounds in the DBP mixture. Overall, without 
considering DBP effects or interaction, we 
found a weak, non significant overall associa-
tion between poly morphisms in each of these 
genes and bladder cancer risk. Associations 
between increasing quartiles of THMs and 
bladder cancer were stronger among subjects 
with GSTT1 +/+ or +/– versus –/–, GSTZ1 
rs1046428 CT or TT versus CC, and CYP2E1 
rs2031920 CC versus CT (no subjects had 
TT), with statistically significant inter-
actions for each of the respective gene vari-
ants. Among the 195 cases and 192 controls 
with GSTT1 present and GSTZ1 rs1046428 
CT/TT, ORs (95% CIs) for quartiles 2, 3, 
and 4 of long-term average THMs were 1.5 
(0.7–3.5), 3.4 (1.4–8.2), and 5.9 (1.8–19.0), 
respectively, relative to quartile 1. We also 
found that main effect estimates for bladder 
cancer in association with these polymor-
phisms varied by THM level, with significant 
associations for all three high-risk genotypes 
among subjects within the highest quartile 
of long-term THMs (Table 4). The super-
multiplicative inter actions between residen-
tial water THM level and polymorphisms in 
GSTT1, GSTZ1, and CYP2E1 are consistent 
with the hypothe sis that these genes influence 
the metabolism of carcinogens in the DBP 
mixture in drinking water.
GSTZ1, conserved over a long evolu-
tionary period, plays a key role in the catabo-
lism of phenyl alanine and tyrosine. In 
addition, GSTZ1 transforms several xeno-
biotic α-haloacid substrates. The HAAs 
dichloroacetic acid, bromo chloro acetic acid, 
and dibromo acetic acid are transformed to 
glyoxylic acid, and 2,2-dichloro propanoic 
acid is metabolized to pyruvic acid (Board and 
Anders 2005). In rodents, dichloro acetic acid 
causes liver cancer and dibromo acetic acid is 
a multi site carcinogen (DeAngelo et al. 1999; 
Melnick et al. 2007). Among GSTZ-depleted 
rats, total body clearance of dihaloacetic acids 
was 3–10 times lower than in rats with nor-
mal levels of GSTzeta (Saghir and Schultz 
2005). Several SNPs in the GSTZ1 gene are 
known (Blackburn et al. 2001). Notably, the 
rs1046428 T allele has been observed to have 
low enzymatic activity for transformation of 
dichloro acetic acid compared with the C allele 
(Blackburn et al. 2001), consistent with our 
finding of elevated risk for individuals with 
this genotype. Many other α-haloacids in the 
DBP mixture that have not been tested for 
carcinogenicity may also serve as substrates 
for GSTZ1 and thereby participate in the 
interaction we observed. Haplotype analysis 
for GSTZ1 did not reveal notable elevated or 
lowered risk of bladder cancer.
A common polymorphic variant of 
GSTT1 is the null form of the allele, which 
is associated with lack of enzymatic activity. 
About 20% of Caucasians are homo zygous 
null for this gene (Raimondi et al. 2006). In 
our control population, 22.5% were homo-
zygous null. Brominated THMs are muta-
genic and carcinogenic and are among the 
Table 3. ORs (95% CIs) for the combined effects of polymorphic forms of GSTT1 and GSTZ1.a
GSTT1 null and GSTZ1 CC GSTT1 present and GSTZ1 CT/TT
Average THM n (cases/controls) OR (95% CI) n (cases/controls) OR (95% CI) pinteractionb
≤ 8.0 19/17 1.0 (reference) 40/51 1.0 (reference)
> 8.0–26.0 25/24 1.1 (0.4–3.0) 35/45 1.5 (0.7–3.5)
26.0–49.0 21/29 1.1 (0.4–3.1) 61/49 3.4 (1.4–8.2)
> 49.0 17/26 1.5 (0.4–5.4) 59/47 5.9 (1.8–19.0)
ptrend 0.57 0.0012 0.0052
aOR (95% CI) from logistic regression adjusted for age (continuous), sex, smoking status (never/former/current), size of 
the municipality of longest residence until 18 years of age, education (three strata), geographic area (six strata), and 
overall quality of interview. Analysis was restricted to subjects with either both GSTT1 null and GSTZ1 rs1046428 CC or 
both GSTT1 present and GSTZ1 rs1046428 CT/TT. bp-Value for multiplicative interaction between the average THM level 
(age 15 to index year) and the indicated genetic characteristic; the calculation uses the median level of average THM 
within each successive quartile.
Table 4. ORs and 95% CIs for five polymorphic genes (GSTT1, GSTZ1, CYP2E1, NAT2, GSTM1) within each of 
four strata of average level of THM in drinking water, in the period from 15 years of age to the index year.a
Average THM (μg/L)
GSTT1 present 
vs. null
GSTZ1 rs1046428, 
CT/TT vs. CC
CYP2E1 rs2031920, 
CC vs. CT/TT
NAT2, slow vs. 
rapid/intermediate
GSTM1, null 
vs. present
≤ 8.0 0.9 (0.5–1.5) 0.7 (0.4–1.2) 0.8 (0.5–1.5) 1.3 (0.8–2.0) 1.8 (1.1–2.9)
> 8.0–26.0 0.9 (0.5–1.6) 1.0 (0.6–1.6) 1.2 (0.7–2.0) 1.5 (0.9–2.5) 1.6 (1.0–2.5)
> 26.0–49.0 1.5 (0.9–2.5) 1.0 (0.6–1.6) 1.9 (1.1–3.3) 1.1 (0.7–1.8) 1.8 (1.2–2.8)
> 49.0 1.8 (1.1–3.1) 1.6 (1.0–2.6) 2.0 (1.1–3.9) 1.4 (0.9–2.2) 1.9 (1.2–2.9)
aThe referent (OR = 1.0) for each cell in the table, specific to a THM level, is indicated in each column heading. OR (95% 
CI) from logistic regression adjusted for age (continuous), sex, smoking status (never/former/current), size of the munici-
pality of longest residence until 18 years of age, education (three strata), geographic area (six strata), and overall quality 
of interview.
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most prevalent DBPs in chlorinated drinking 
water. Pegram et al. (1997) and DeMarini 
et al. (1997) demon strated that in Salmonella 
transfected with rat GSTT1‑1+, brominated 
THMs are activated to mutagens, and they 
identified the specific mutagenic transitions 
(GC→AT) involved. Dibromonitromethane, 
a DBP that has not been tested for carcino-
genicity, is also activated to a mutagen by 
a transgenic strain of Salmonella expressing 
GSTT1-1 (Kundu et al. 2004). Authors of 
both in vivo and in vitro studies have sug-
gested a model whereby brominated THMs, 
after dermal absorption and inhalation, escape 
first-pass hepatic metabolism and reach target 
tissues in the urinary tract where the relative 
proportion of GSTT1 and oxidative enzymes 
is more favorable for GSTT1-mediated 
metabo lism (Landi et al. 1999; Ross and 
Pegram 2003, 2004). In the bladder, the bro-
minated THM could be activated to mutagens 
in a GSTT1+ person, leading to increased 
bladder cancer risk. Findings from experimen-
tal exposures to humans are also consistent 
with our observations. Exposure of humans 
to BDCM showed that 2 of 10 subjects, each 
of whom were GSTT1 null and had low 
CYP2E1 activity, had the lowest total BDCM 
metabolism (i.e., the highest blood levels of 
unmetabolized BDCM) and the highest peak 
levels of mutagenicity in their urine because 
of unmetabolized urinary BDCM (Leavens 
et al. 2007). In that experimental study, der-
mal exposure to BDCM resulted in blood 
levels 25–130 times higher than those from 
oral exposure, indicating that this is a major 
route of exposure to brominated THM. This 
is consistent with elevated risk for bladder 
cancer via showering, bathing, and/or swim-
ming (Villanueva et al. 2007). Supporting our 
observation of a positive interaction of long-
term DBPs with GSTT1+ is a finding of low 
risk among populations with the GSTT1 null 
genotype from an analysis of international 
data (Kim et al. 2002). Renal cell carcinoma 
risk is elevated among GSTT1+ individuals 
with occupational exposure to pesticides or 
to solvents such as trichloro ethylene, possibly 
through a similar mechanism (Buzio et al. 
2003; Karami et al. 2008).
The phase I metabolic enzyme CYP2E1 
oxidizes a wide variety of alkanes, alkenes, and 
aromatic and halogenated hydrocarbons and 
activates many of them to carcinogenic com-
pounds (Bolt et al. 2003). Several chemical 
species in the DBP mixture are potential 
substrates of CYP2E1. Our data, revealing 
a signifi cant interaction between the level of 
long-term DBP exposure and the –1054C>T 
(sometimes designated as –1053C>T) 
rs2031920 SNP of CYP2E1, suggests the possi-
bility of carcinogenic activation of one or more 
constituents of the DBP mixture by the com-
mon form of this enzyme. However, we make 
this observation cautiously. Although CYP2E1 
levels are partially determined by genetic fac-
tors, the enzyme is highly inducible by alco-
hol and other factors, and its synthesis can be 
inhibited by food constituents (Oneta et al. 
2002; Perocco et al. 2006). We were unable 
to control for these latter effects. The relatively 
small number of subjects with the rs2031920 
CT/TT genotype (37 cases, 42 controls) con-
tributed to the relative instability of this find-
ing. In addition, our observation of an OR 
< 1.0 among the most highly exposed subjects 
with this genotype suggests a cautious interpre-
tation of the CYP2E1 findings.
It is unlikely that the aromatic amine sub-
strates for NAT2, found in tobacco products 
and linked with bladder cancer, are pres-
ent in the DBP mixture (Richardson 2003). 
However, DBP mixtures are complex, and 
we felt it worthwhile to evaluate the possi-
bility of an interaction between DBPs and 
slow/rapid acetylation genotypes of NAT2 
in risk of bladder cancer. Our expectation of 
little or no interaction was borne out in the 
data. The mechanism underlying associations 
between bladder cancer and the GSTM1-null 
genotype is not yet well understood (Garcia-
Closas et al. 2005). Our data indicated that 
the strength of the association of bladder 
cancer with GSTM1 null is not affected by 
exposure to DBPs.
As our primary metric of exposure 
to DBPs, we used the long-term average 
THM concentration at the household level 
(Villanueva et al. 2007). DBPs are a complex 
mixture of halogenated organics whose com-
position and concentration vary in time and 
space. Hundreds of individual chemical spe-
cies have been identified (Richardson 2003). 
THMs and HAAs are the chemical groups 
found at the highest concentrations in most 
mixtures, typically accounting for 20–30% 
of bound halogen. Although there is variabil-
ity among the chemical components of DBP 
mixtures, the correlation coefficient between 
THMs and HAAs is usually > 0.7, and THM 
levels have been used in many epidemiologic 
studies as a surrogate for the full mixture. 
Although THMs and halo acetic acids are the 
most common chemical species within the 
DBP mixture, they may not be the most toxic/
carcinogenic, and one or more of the poly-
morphisms of interest may be acting in impor-
tant ways on other compounds with levels 
that are correlated with THMs.
Elevated levels of THMs and other DBPs 
are common in chlorinated swimming pools 
and cause elevated THM blood levels among 
swimmers (Aggazzotti et al. 1998). We found 
no significant interaction of the poly morphisms 
studied here with ever use of swimming pools. 
However, the number of pool users was small, 
findings were not statistically stable, and 
the relative concentrations of various DBPs 
in pools differ from those in drinking water, 
precluding interpretation of these findings.
In this hospital-based study, we had a high 
response rate among both cases and controls, 
and all diagnoses were histologically con-
firmed. Controls were matched to cases on age 
group, sex, and geographic area of residence 
at diagnosis. Although matching on area of 
residence may result in over matching for type 
of water, possibly biasing relative risks toward 
the null, most hospital catchment areas were 
large enough to provide substantial variabil-
ity in water sources. We examined residential 
history since 15 years of age, so that persons 
who may have had the same water source at 
the time of the study could easily have lived 
in other places previously. We conducted this 
analysis on a subset of the full study popula-
tion, namely, subjects with genotype data and 
reliable information on DBP exposures for at 
least 70% of years between 15 years of age and 
diagnosis (cases) or interview (controls). We 
included 680 cases (of 1,219 in the full study) 
and 714 controls (of 1,271), and associations 
between bladder cancer and cigarette smoking, 
long-term exposure to THMs, and the main 
effects of NAT2 and GSTM1 (Garcia-Closas 
et al. 2005; Samanic et al. 2006; Villanueva 
et al. 2007) were comparable with those esti-
mated for the full study population, suggesting 
that this subgroup is comparable with the full 
set of patients recruited to the study.
Bladder cancer risk has been consistently 
linked with long-term exposure to DBPs, a 
complex mixture of halogenated compounds 
in drinking water created when chlorine is 
used as a disinfectant (Cantor et al. 1998; King 
and Marrett 1996; McGeehin et al. 1993; 
Villanueva et al. 2004). Experimental evidence 
of mutagenicity and carcinogenicity supports 
these findings (Komulainen 2004; Richardson 
et al. 2007). Prior to this study, evidence was 
considered inadequate to firmly support a 
causal role for DBPs in the etiology of blad-
der cancer, primarily for two reasons. First, 
relative risks reported by most epidemiologic 
studies have been modest, with ORs typically 
< 2, posing the possibility that observed asso-
ciations may be due to bias. Second, there have 
been inconsistencies in sex-specific findings. 
The evidence of elevated bladder cancer risk 
from the present study, based on inter action of 
DBPs with candidate genes known to be in the 
biotransformation pathways of known carcino-
gens and mutagens in the mixture, strengthens 
the case for a causal interpretation. Because 
> 20% of the controls in our study population 
were joint carriers of the high-risk genotypes of 
the three genes we evaluated, our findings may 
have significant public health implications in 
relation to preventing cancers following expo-
sure to these water contaminants. Early replica-
tion of these findings in another population 
is warranted.
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Hospital de Sant Boi, Sant Boi de Llobregat, 
Barcelona
Consorci Hospitalari Parc Tauli, Sabadell
Centre Hospitalari i Cardiologic, Manresa, 
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Hospital Universitario de Canarias, 
La Laguna, Tenerife
Hospital Universitario Nuestra Senora de la 
Candelaria, Tenerife
Hospital General Universitario de Elche, 
Universidad Miguel Hernandez, Elche, 
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Universidad de Oviedo, Oviedo, Asturias
Hospital San Agustin, Aviles, Asturias
Hospital Central Covadonga, Oviedo, Asturias
Hospital Central General, Oviedo, Asturias
Hospital de Cabuenes, Gijon, Asturias
Hospital de Jove, Gijon, Asturias
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Hospital Alvarez-Buylla, Mieres, Asturias
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Hospital Carmen y Severo Ochoa, Cangas, 
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